Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Dosing Strategies of Amikacin for Drug-Resistant Bacterial Infections
ChiCTR2400088648Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of amikacin in Gram-negative bacterial infection, bloodstream infection (BSI), endocarditis (IE) and 6 more, sponsored by Huashan Hospital. Primary endpoint: amikacin plasma concentration. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
amikacin
03
Conditions
Gram-negative bacterial infectionbloodstream infection (BSI)endocarditis (IE)pneumoniapulmonary infection
Beyond the preview
Go deeper on ChiCTR2400088648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088648.